Isolation of miRNAs that target EGFR mRNA in human lung cancer

Biochemical and Biophysical Research Communications

Volumn 420, Issue 2, 2012, Pages 411-416

  Yamaguchi, Gaku ^a   Takanashi, Masakatsu ^a   Tanaka, Masami ^a   Fujita, Koji ^a   Ohira, Tatsuo ^a   Kuroda, Masahiko ^a   Ikeda, Norihiko ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

EGFR; Lung cancer; MiR 542 5p

Indexed keywords

ARGONAUTE 2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; MICRORNA; MICRORNA 542 5P; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOINFORMATICS; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TISSUE; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; LUNG CANCER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ANALYSIS; RNA ISOLATION; UPREGULATION;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; LUNG NEOPLASMS; MICRORNAS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; UP-REGULATION;

EID: 84862787587     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.03.008     Document Type: Article

References (26)

1. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, C. Smigal, M.J. Thun, Cancer statistics, 2006, CA: A Cancer Journal for Clinicians 56 (2006) 106-130.
2. Scagliotti G.V., Selvaggi G., Novello S., Hirsch F.R. The biology of epidermal growth factor receptor in lung cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2004, 10:4227s-4232s.
3. Arteaga C.L. EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2003, 21:289s-291s.
4. Bianco R., Troiani T., Tortora G., Ciardiello F. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. Endocrine-Related Cancer 2005, 12(Suppl 1):S159-S171.
5. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
6. Inamura K., Togashi Y., Nomura K., Ninomiya H., Hiramatsu M., Satoh Y., Okumura S., Nakagawa K., Ishikawa Y. Let-7 microRNA expression is reduced in bronchioloalveolar carcinoma, a non-invasive carcinoma, and is not correlated with prognosis. Lung Cancer 2007, 58:392-396.
7. Takamizawa J., Konishi H., Yanagisawa K., Tomida S., Osada H., Endoh H., Harano T., Yatabe Y., Nagino M., Nimura Y., Mitsudomi T., Takahashi T. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Research 2004, 64:3753-3756.
8. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., Sweet-Cordero A., Ebert B.L., Mak R.H., Ferrando A.A., Downing J.R., Jacks T., Horvitz H.R., Golub T.R. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
9. Johnson S.M., Grosshans H., Shingara J., Byrom M., Jarvis R., Cheng A., Labourier E., Reinert K.L., Brown D., Slack F.J. RAS is regulated by the let-7 microRNA family. Cell 2005, 120:635-647.
10. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., Visone R., Iorio M., Roldo C., Ferracin M., Prueitt R.L., Yanaihara N., Lanza G., Scarpa A., Vecchione A., Negrini M., Harris C.C., Croce C.M. A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:2257-2261.
11. Grimson A., Farh K.K., Johnston W.K., Garrett-Engele P., Lim L.P., Bartel D.P. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Molecular Cell 2007, 27:91-105.
12. Calin G.A., Ferracin M., Cimmino A., Di Leva G., Shimizu M., Wojcik S.E., Iorio M.V., Visone R., Sever N.I., Fabbri M., Iuliano R., Palumbo T., Pichiorri F., Roldo C., Garzon R., Sevignani C., Rassenti L., Alder H., Volinia S., Liu C.G., Kipps T.J., Negrini M., Croce C.M. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. The New England Journal of Medicine 2005, 353:1793-1801.
13. Weidhaas J.B., Babar I., Nallur S.M., Trang P., Roush S., Boehm M., Gillespie E., Slack F.J. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Research 2007, 67:11111-11116.
14. Webster R.J., Giles K.M., Price K.J., Zhang P.M., Mattick J.S., Leedman P.J. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. The Journal of Biological Chemistry 2009, 284:5731-5741.
15. Maziere P., Enright A.J. Prediction of microRNA targets. Drug Discovery Today 2007, 12:452-458.
16. Griffiths-Jones S., Saini H.K., van Dongen S., Enright A.J. MiRBase: tools for microRNA genomics. Nucleic Acids Research 2008, 36:D154-D158.
17. Tsuchida A., Ohno S., Wu W., Borjigin N., Fujita K., Aoki T., Ueda S., Takanashi M., Kuroda M. MiR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer. Cancer Science 2011, 102:2264-2271.
18. Gazdar A.F., Shigematsu H., Herz J., Minna J.D. Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?. Trends in Molecular Medicine 2004, 10:481-486.
19. Orom U.A., Nielsen F.C., Lund A.H. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Molecular Cell 2008, 30:460-471.
20. Herbst R.S., Fukuoka M., Baselga J. Gefitinib-a novel targeted approach to treating cancer. Nature reviews. Cancer 2004, 4:956-965.
21. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nature reviews. Cancer 2007, 7:169-181.
22. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England Journal of Medicine 2004, 350:2129-2139.
23. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
24. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., Majem M., Lopez-Vivanco G., Isla D., Provencio M., Insa A., Massuti B., Gonzalez-Larriba J.L., Paz-Ares L., Bover I., Garcia-Campelo R., Moreno M.A., Catot S., Rolfo C., Reguart N., Palmero R., Sanchez J.M., Bastus R., Mayo C., Bertran-Alamillo J., Molina M.A., Sanchez J.J., Taron M. Screening for epidermal growth factor receptor mutations in lung cancer. The New England Journal of Medicine 2009, 361:958-967.
25. Bray I., Tivnan A., Bryan K., Foley N.H., Watters K.M., Tracey L., Davidoff A.M., Stallings R.L. MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma. Cancer Letters 2011, 303:56-64.
26. Acs G., Zhang P.J., McGrath C.M., Acs P., McBroom J., Mohyeldin A., Liu S., Lu H., Verma A. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. American Journal of Pathology 2003, 162:1789-1806.